Anti-HIV Agents

• 

  Subject Areas on Research

  • "It's because I think too much": Perspectives and experiences of adults with hypertension engaged in HIV care in northern Tanzania. 
  • "We're Not Done". 
  • 'Well, It's the Risk of the Unknown… Right?': A Qualitative Study of Perceived Risks and Benefits of HIV Cure Research in the United States. 
  • A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity. 
  • A Qualitative Exploration of Various Stigmas Impacting HIV Pre-Exposure Prophylaxis (PrEP) Uptake Among African American Young Adults. 
  • A Review of Recent Literature on Trauma Among Individuals Living with HIV. 
  • A comparison of height and weight velocity as a part of the composite endpoint in pediatric HIV. 
  • A counseling intervention to address HIV stigma at entry into antenatal care in Tanzania (Maisha): study protocol for a pilot randomized controlled trial. 
  • A group-based mental health intervention for young people living with HIV in Tanzania: results of a pilot individually randomized group treatment trial. 
  • A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 Team. 
  • A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection. 
  • A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. AIDS Clinical Trials Group 240 Team. 
  • A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. 
  • A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. 
  • A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team. 
  • A semiparametric likelihood approach to joint modeling of longitudinal and time-to-event data. 
  • A social cognitive model of health for HIV-positive adults receiving care in India. 
  • AIDS 2016: from aspiration to implementation. 
  • AIDS-associated diarrhea and wasting in Northeast Brazil is associated with subtherapeutic plasma levels of antiretroviral medications and with both bovine and human subtypes of Cryptosporidium parvum. 
  • Acceptability of a Community Health Worker Program to Link High-Risk People in Jail to HIV Pre-Exposure Prophylaxis. 
  • Acceptability of a group intervention for initiates of antiretroviral therapy in Tanzania. 
  • Acceptability of pre-exposure prophylaxis among men who have sex with men and transgender women in Northern Thailand. 
  • Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials. 
  • Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models. 
  • Acute renal failure after initiation of tenofovir disoproxil fumarate. 
  • Adaptations across clinical sites of an integrated treatment model for persons with HIV and substance abuse. 
  • Addressing Polypharmacy in Older Adults Living With HIV. 
  • Addressing the challenges of adherence. 
  • Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. 
  • Adherence to antiretroviral therapy among HIV-infected children receiving care at Kilimanjaro Christian Medical Centre (KCMC), Northern Tanzania: A cross- sectional analytical study. 
  • Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. 
  • Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission. 
  • Advancing the HIV Pre-Exposure Prophylaxis Continuum: A Collaboration Between a Public Health Department and a Federally Qualified Health Center in the Southern United States. 
  • Advantages to Using Social-Behavioral Models of Medication Adherence in Research and Practice. 
  • An action agenda for HIV and sex workers. 
  • An educational initiative in response to identified PrEP prescribing needs among PCPs in the Southern U.S. 
  • An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. 
  • Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment. 
  • Anti-AIDS agents 49. Synthesis, anti-HIV, and anti-fusion activities of IC9564 analogues based on betulinic acid. 
  • Anti-AIDS agents 69. Moronic acid and other triterpene derivatives as novel potent anti-HIV agents. 
  • Anti-AIDS agents 79. Design, synthesis, molecular modeling and structure-activity relationships of novel dicamphanoyl-2',2'-dimethyldihydropyranochromone (DCP) analogs as potent anti-HIV agents. 
  • Anti-AIDS agents 81. Design, synthesis, and structure-activity relationship study of betulinic acid and moronic acid derivatives as potent HIV maturation inhibitors. 
  • Anti-AIDS agents 82: synthesis of seco-(3'R,4'R)-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (DCK) derivatives as novel anti-HIV agents. 
  • Anti-AIDS agents 85. Design, synthesis, and evaluation of 1R,2R-dicamphanoyl-3,3-dimethyldihydropyrano-[2,3-c]xanthen-7(1H)-one (DCX) derivatives as novel anti-HIV agents. 
  • Anti-AIDS agents 86. Synthesis and anti-HIV evaluation of 2',3'-seco-3'-nor DCP and DCK analogues. 
  • Anti-AIDS agents 87. New bio-isosteric dicamphanoyl-dihydropyranochromone (DCP) and dicamphanoyl-khellactone (DCK) analogues with potent anti-HIV activity. 
  • Anti-AIDS agents 90. novel C-28 modified bevirimat analogues as potent HIV maturation inhibitors. 
  • Anti-AIDS agents--XXVII. Synthesis and anti-HIV activity of betulinic acid and dihydrobetulinic acid derivatives. 
  • Anti-AIDS agents. 34. Synthesis and structure-activity relationships of betulin derivatives as anti-HIV agents. 
  • Anti-AIDS agents. 42. Synthesis and anti-HIV activity of disubstituted (3'R,4'R)-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone analogues. 
  • Anti-AIDS agents. 60. Substituted 3'R,4'R-di-O-(-)-camphanoyl-2',2'-dimethyldihydropyrano[2,3-f]chromone (DCP) analogues as potent anti-HIV agents. 
  • Anti-AIDS agents. 78. Design, synthesis, metabolic stability assessment, and antiviral evaluation of novel betulinic acid derivatives as potent anti-human immunodeficiency virus (HIV) agents. 
  • Anti-HIV Agents 45 and Antitumor Agents 205. Two New Sesquiterpenes, Leitneridanins A and B, and the Cytotoxic and Anti-HIV Principles from Leitneria floridana 
  • Anti-HIV Macrocyclic Daphnane Orthoesters with an Unusual Macrocyclic Ring from Edgeworthia chrysantha. 
  • Anti-HIV Potential of Beesioside I Derivatives as Maturation Inhibitors: Synthesis, 3D-QSAR, Molecular Docking and Molecular Dynamics Simulations. 
  • Anti-HIV Tigliane Diterpenoids from Wikstroemia scytophylla. 
  • Anti-inflammatory and Anti-HIV Compounds from Swertia bimaculata. 
  • Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds. 
  • Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor. 
  • Antiretroviral Treatment Interruptions Among Black and Latina Transgender Women Living with HIV: Characterizing Co-occurring, Multilevel Factors Using the Gender Affirmation Framework. 
  • Antiretroviral chemoprophylaxis: PROUD and pragmatism. 
  • Antiretroviral medications: adverse effects on the kidney. 
  • Antiretroviral rounds. A communication conundrum. 
  • Antiretroviral therapy effects on genetic and morphologic end points in lymphocytes and sperm of men with human immunodeficiency virus infection. 
  • Antiretroviral therapy enrollment characteristics and outcomes among HIV-infected adolescents and young adults compared with older adults--seven African countries, 2004-2013. 
  • Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation. 
  • Antiretroviral therapy restores diversity in the T-cell receptor Vbeta repertoire of CD4 T-cell subpopulations among human immunodeficiency virus type 1-infected children and adolescents. 
  • Antiretroviral therapy where resources are limited. 
  • Antiretroviral therapy: evaluating the new era in HIV treatment. 
  • Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV. 
  • Assessing the effect of Measurement-Based Care depression treatment on HIV medication adherence and health outcomes: rationale and design of the SLAM DUNC Study. 
  • Assessing the use of surveillance data to estimate the impact of prevention interventions on HIV incidence in cluster-randomized controlled trials. 
  • Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire. 
  • Association of HIV serostatus and metabolic syndrome with neurobehavioral disturbances. 
  • Association of aflatoxin B1 levels with mean CD4 cell count and uptake of ART among HIV infected patients: A prospective study. 
  • Association of race and gender with use of antiretroviral therapy among HIV-infected individuals in the Southeastern United States. 
  • Association of unmet needs for support services with medication use and adherence among HIV-infected individuals in the southeastern United States. 
  • Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. 
  • Bacteremic disseminated tuberculosis in sub-saharan Africa: a prospective cohort study. 
  • Behavioral and biomedical combination strategies for HIV prevention. 
  • Benefits, risk, and uncertainty: preferences of antiretroviral-naïve African Americans for HIV treatments. 
  • Betulinic acid derivatives as HIV-1 antivirals. 
  • Betulinic acid derivatives as human immunodeficiency virus type 2 (HIV-2) inhibitors. 
  • Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1. 
  • Bifunctional anti-human immunodeficiency virus type 1 small molecules with two novel mechanisms of action. 
  • Bipolar disorder is associated with HIV transmission risk behavior among patients in treatment for HIV. 
  • Blocking HIV-1 entry by a gp120 surface binding inhibitor. 
  • Brief Report: Blood and Genital Fluid Viral Load Trajectories Among Treated and Untreated Persons With Acute HIV Infection in Malawi. 
  • Brief Report: Frequency of Monitoring Kidney Function in HIV-Uninfected Persons Using Daily Oral Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis. 
  • Brief Report: Kidney Dysfunction Does Not Contribute Significantly to Antiretroviral Therapy Modification in Treatment-Naive PLWH Receiving Initial ART. 
  • CD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials. 
  • Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action. 
  • Capacity of health-care facilities to deliver HIV treatment and care services, Northern Tanzania, 2004. 
  • Cardiovascular Complications of HIV in Endemic Countries. 
  • Caregiver role in HIV medication adherence among HIV-infected orphans in Tanzania. 
  • Carolignans from the Aerial Parts of Euphorbia sikkimensis and Their Anti-HIV Activity. 
  • Catalytic enantioselective olefin metathesis in natural product synthesis. Chiral metal-based complexes that deliver high enantioselectivity and more. 
  • Caveats associated with the use of human cervical tissue for HIV and microbicide research. 
  • Challenge of coadministering antiretroviral therapy and oral anticoagulants in HIV-positive patients. 
  • Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial. 
  • Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS. 
  • Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine. 
  • Changing Patterns and Factors Associated With Mode of Delivery Among Pregnant Women With Human Immunodeficiency Virus Infection in the United States. 
  • Changing antiretroviral therapy in the setting of virologic relapse: review of the current literature. 
  • Characteristics of HIV voluntary counseling and testing clients before and during care and treatment scale-up in Moshi, Tanzania. 
  • Childhood abuse and initial presentation for HIV care: an opportunity for early intervention. 
  • Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments. 
  • Chronic multifocal retinal infiltrates in patients infected with human immunodeficiency virus. 
  • Clinical and laboratory characteristics of a large cohort of symptomatic, human immunodeficiency virus-infected infants and children. AIDS Clinical Trials Group Protocol 152 Study Team. 
  • Clinical assessment of medication adherence among HIV-infected children: examination of the Treatment Interview Protocol (TIP). 
  • Clinical implications of discordant viral and immune outcomes following protease inhibitor containing antiretroviral therapy for HIV-infected children. 
  • Clonal amplification and maternal-infant transmission of nevirapine-resistant HIV-1 variants in breast milk following single-dose nevirapine prophylaxis. 
  • Coadministration of zidovudine and interleukin-2 increases absolute CD4 cells in subjects with Walter Reed stage 2 human immunodeficiency virus infection: results of ACTG protocol 042. 
  • Combination HIV prevention among MSM in South Africa: results from agent-based modeling. 
  • Combination antiretroviral therapy results in a rapid increase in T cell receptor variable region beta repertoire diversity within CD45RA CD8 T cells in human immunodeficiency virus-infected children. 
  • Combination antiretroviral therapy. 
  • Combination therapy with anti-HIV-1 antibodies maintains viral suppression. 
  • Combination therapy with stavudine (d4T) plus didanosine (ddI) in children with human immunodeficiency virus infection. The Pediatric AIDS Clinical Trials Group 327 Team. 
  • Community perspectives of South African adolescents' experiences seeking treatment at local HIV clinics and how such clinics may influence engagement in the HIV treatment cascade: a qualitative study. 
  • Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview. 
  • Compartmental transport model of microbicide delivery by an intravaginal ring. 
  • Conjugates of betulin derivatives with AZT as potent anti-HIV agents. 
  • Context specific HIV risk: evidence from screening into the southern pre-exposure prophylaxis study (SPECS). 
  • Coping strategies and patterns of alcohol and drug use among HIV-infected patients in the United States Southeast. 
  • Core chemotype diversification in the HIV-1 entry inhibitor class using field-based bioisosteric replacement. 
  • Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group. 
  • Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV. 
  • Cost-effectiveness of mandatory compared with voluntary screening for human immunodeficiency virus in pregnancy. 
  • Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease. 
  • Curing HIV: Seeking to Target and Clear Persistent Infection. 
  • Daphneodorins A-C, Anti-HIV Gnidimacrin Related Macrocyclic Daphnane Orthoesters from Daphne odora. 
  • Daphnepedunins A-F, Anti-HIV Macrocyclic Daphnane Orthoester Diterpenoids from Daphne pedunculata. 
  • Decreasing CD4+ T-cell count during suppressed or low-level viraemia in patients with HIV infection. 
  • Deducing Mucosal Pharmacokinetics and Pharmacodynamics of the Anti-HIV Molecule Tenofovir from Measurements in Blood. 
  • Depression and Engagement in Care Among Newly Diagnosed HIV-Infected Adults in Johannesburg, South Africa. 
  • Depression, sexual behavior, and HIV treatment outcomes among transgender women, cisgender women and men who have sex with men living with HIV in Brazil and Thailand: a short report. 
  • Design and synthesis of human immunodeficiency virus entry inhibitors: sulfonamide as an isostere for the alpha-ketoamide group. 
  • Design, Synthesis, and Mechanism Study of Benzenesulfonamide-Containing Phenylalanine Derivatives as Novel HIV-1 Capsid Inhibitors with Improved Antiviral Activities. 
  • Design, synthesis and structure-activity relationships of 4-phenyl-1H-1,2,3-triazole phenylalanine derivatives as novel HIV-1 capsid inhibitors with promising antiviral activities. 
  • Design, synthesis, and antiviral activity of phenylalanine derivatives as HIV-1 capsid inhibitors. 
  • Design, synthesis, and biologic evaluation of novel galloyl derivatives as HIV-1 RNase H inhibitors. 
  • Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase. 
  • Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates. 
  • Design, synthesis, and structure activity relationship analysis of new betulinic acid derivatives as potent HIV inhibitors. 
  • Detection of minor drug-resistant populations by parallel allele-specific sequencing. 
  • Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. 
  • Developmental pharmacokinetic changes of Lamivudine in infants and children. 
  • Diagnosing Rhodococcus equi infections in a setting where tuberculosis is highly endemic: a double challenge. 
  • Differences between HIV-Infected men and women in antiretroviral therapy outcomes - six African countries, 2004-2012. 
  • Diminished physical function in older HIV-infected adults in the Southeastern U.S. despite successful antiretroviral therapy. 
  • Discovery and synthesis of novel beesioside I derivatives with potent anti-HIV activity. 
  • Discovery of diarylpyridine derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. 
  • Discovery of phenylalanine derivatives as potent HIV-1 capsid inhibitors from click chemistry-based compound library. 
  • Discovery of potential dual-target prodrugs of HIV-1 reverse transcriptase and nucleocapsid protein 7. 
  • Dismantling Barriers and Transforming the Future of Pre-Exposure Prophylaxis Uptake in Young Black and Latinx Sexual Minority Men and Transgender Women. 
  • Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapy. 
  • Diterpenes from the stem bark of Euphorbia neriifolia and their in vitro anti-HIV activity. 
  • Diverse contexts and social factors among young cisgender men and transgender women who sell or trade sex in Bangkok and Pattaya, Thailand: formative research for a PrEP program implementation study. 
  • Drug Use Mediates the Relationship Between Depressive Symptoms and Adherence to ART Among Recently Incarcerated People Living with HIV. 
  • Drug companies cut HIV drug prices in the developing world. 
  • Drug susceptibility and resistance mutations after first-line failure in resource limited settings. 
  • Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus. 
  • Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. 
  • Durability of antiretroviral therapy and predictors of virologic failure among perinatally HIV-infected children in Tanzania: a four-year follow-up. 
  • Durhamycin A, a potent inhibitor of HIV Tat transactivation. 
  • Dynamics of HIV neutralization by a microbicide formulation layer: biophysical fundamentals and transport theory. 
  • Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164. 
  • Early cardiac dysfunction in children and young adults with perinatally acquired HIV. 
  • Early intensification with abacavir in subjects at high risk for incomplete viral suppression. 
  • Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania. 
  • Economic evaluation of ART in resource-limited countries. 
  • Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. 
  • Efavirenz: innocent bystander or direct nephrotoxin? 
  • Effect of Postnatal HIV Treatment on Clinical Mastitis and Breast Inflammation in HIV-Infected Breast-feeding Women. 
  • Effect of directly observed antiretroviral therapy compared to self-administered antiretroviral therapy on adherence and virological outcomes among HIV-infected prisoners: a randomized controlled pilot study. 
  • Effect of highly active antiretroviral therapy and thymic transplantation on immunoreconstitution in HIV infection. 
  • Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia. 
  • Effectiveness of etoposide chemomobilization in lymphoma patients undergoing auto-SCT. 
  • Effects of Antiretroviral Therapy and Depressive Symptoms on All-Cause Mortality Among HIV-Infected Women. 
  • Effects of gel volume on pharmacokinetics for vaginal and rectal applications of combination DuoGel-IQB4012, a dual chamber-dual drug HIV microbicide gel, in pigtailed macaques. 
  • Effects of raltegravir on 2-long terminal repeat circle junctions in HIV type 1 viremic and aviremic patients. 
  • Efficacy and safety of hematopoietic stem cell remobilization with plerixafor+G-CSF in adult patients with germ cell tumors. 
  • Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. 
  • Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. 
  • Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection. 
  • Elevated frequencies of micronucleated erythrocytes in infants exposed to zidovudine in utero and postpartum to prevent mother-to-child transmission of HIV. 
  • Elevations in Serum Creatinine With Tenofovir-Based HIV Pre-Exposure Prophylaxis: A Meta-Analysis of Randomized Placebo-Controlled Trials. 
  • Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. 
  • Ending AIDS as a public health threat by 2030: Scientific Developments from the 2016 INTEREST Conference in Yaoundé, Cameroon. 
  • Engineering a therapeutic lectin by uncoupling mitogenicity from antiviral activity. 
  • Episodic Use of Pre-Exposure Prophylaxis Among Young Cisgender Women in Siaya County, Kenya. 
  • Essential nursing competencies related to HIV and AIDS: Executive summary. 
  • Estimating correlation by using a general linear mixed model: evaluation of the relationship between the concentration of HIV-1 RNA in blood and semen. 
  • Estimating the parameters in the Cox model when covariate variables are measured with error. 
  • Ethics of placebo-controlled trials of zidovudine to prevent the perinatal transmission of HIV in the Third World. 
  • Evaluating marker-guided treatment selection strategies. 
  • Evaluation of longitudinal clinical outcomes and adherence to care among HIV-infected refugees. 
  • Evaluation of the synthesis of sialic acid-PAMAM glycodendrimers without the use of sugar protecting groups, and the anti-HIV-1 properties of these compounds. 
  • Evolution of drug-resistant viral populations during interruption of antiretroviral therapy. 
  • Examination of the Role of Religious and Psychosocial Factors in HIV Medication Adherence Rates. 
  • Examining Factors that Impact Intentions to Use Pre-Exposure Prophylaxis Among African-American Young Adults. 
  • Exosome markers associated with immune activation and oxidative stress in HIV patients on antiretroviral therapy. 
  • Exploring the HIV continuum of care among young black MSM. 
  • Expression levels of TLRs involved in viral recognition in PBMCs from HIV-1-infected patients failing antiretroviral therapy. 
  • External Quality Assessment for Next-Generation Sequencing-Based HIV Drug Resistance Testing: Unique Requirements and Challenges. 
  • FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. 
  • Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients. 
  • Feasibility, Acceptability, and Preliminary Efficacy of a Gamified Mobile Health Contingency Management Intervention for PrEP Adherence Among Black MSM. 
  • Feasibility, safety, acceptability, and preliminary efficacy of measurement-based care depression treatment for HIV patients in Bamenda, Cameroon. 
  • Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection. 
  • Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability. 
  • Fluorinated betulinic acid derivatives and evaluation of their anti-HIV activity. 
  • Full depth measurement of tenofovir transport in rectal mucosa using confocal Raman spectroscopy and optical coherence tomography. 
  • Future directions in pharmacogenomics discovery in cardiovascular disease. 
  • Getting youth PrEPared: adolescent consent laws and implications for the availability of PrEP among youth in countries outside of the United States. 
  • Global health and university patents. 
  • Glomerular filtration rate estimated using creatinine, cystatin C or both markers and the risk of clinical events in HIV-infected individuals. 
  • Gnidimacrin, a Potent Anti-HIV Diterpene, Can Eliminate Latent HIV-1 Ex Vivo by Activation of Protein Kinase C β. 
  • Growth as a part of the composite endpoint in paediatric antiretroviral clinical trials. 
  • Growth patterns reflect response to antiretroviral therapy in HIV-positive infants: potential utility in resource-poor settings. 
  • Growth, survival and viral load in symptomatic childhood human immunodeficiency virus infection. 
  • HIV Antiretroviral Treatment and Pre-exposure Prophylaxis in Transgender Individuals. 
  • HIV Drug Resistance. 
  • HIV Preexposure Prophylaxis Implementation at Local Health Departments: A Statewide Assessment of Activities and Barriers. 
  • HIV Prevention in a Time of COVID-19: A Report from the HIVR4P // Virtual Conference 2021. 
  • HIV Resistance and Prevention of Mother-to-Child Transmission Regimen in HIV-Infected Infants in Northern Tanzania. 
  • HIV Testing and PrEP Use in a National Probability Sample of Sexually Active Transgender People in the United States. 
  • HIV and pregnancy: considerations for nursing practice. 
  • HIV care and treatment for children in resource-limited settings. 
  • HIV entry inhibitors: progress in development and application. 
  • HIV fusion and its inhibition. 
  • HIV infection: treatment outcomes in older and younger adults. 
  • HIV persistence in the gut mucosa of HIV-infected subjects undergoing antiretroviral therapy correlates with immune activation and increased levels of LPS. 
  • HIV pre-exposure prophylaxis. 
  • HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. 
  • HIV, prisoners, and human rights. 
  • HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds. 
  • HIV-1 Drug Resistance and Virologic Outcomes Among Tanzanian Youth Living With HIV. 
  • HIV-1 RNA levels and the development of clinical disease. North American Lamivudine HIV Working Group. 
  • HIV-1 and HIV-Associated Nephropathy 25 Years Later. 
  • HIV-1 drug resistance in antiretroviral-naive individuals with HIV-1-associated tuberculous meningitis initiating antiretroviral therapy in Vietnam. 
  • HIV-1 fitness and macrophages. 
  • HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth. 
  • HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells. 
  • HIV-associated nephropathy in the era of antiretroviral therapy. 
  • HIV-associated nephropathy is a late, not early, manifestation of HIV-1 infection. 
  • HIV. A clever hijacker of the immune system. 
  • HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. 
  • HIV/HCV-coinfected natural viral suppressors have better virologic responses to PEG-IFN and ribavirin than ARV-treated HIV/HCV patients. 
  • Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. 
  • Hepatitis C and the risk of kidney disease and mortality in veterans with HIV. 
  • Heterobiaryl human immunodeficiency virus entry inhibitors. 
  • Heterogeneous Patient Preferences for Modern Antiretroviral Therapy: Results of a Discrete Choice Experiment. 
  • High prevalence of cervical squamous intraepithelial lesions in women on antiretroviral therapy in Cameroon: Is targeted screening feasible? 
  • How do North Carolina prenatal care providers counsel and test pregnant women for HIV? Survey measures knowledge of HIV testing benefits. 
  • Human immunodeficiency virus type 1 protease genotype predicts immune and viral responses to combination therapy with protease inhibitors (PIs) in PI-naive patients. 
  • Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3',3'-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag. 
  • Hyper-excretion of human immunodeficiency virus type 1 RNA in saliva. 
  • Hyperlactataemia syndromes associated with HIV therapy. 
  • Hypertension Among HIV-infected Patients in Clinical Care, 1996-2013. 
  • IAPAC Guidelines for Optimizing the HIV Care Continuum for Adults and Adolescents. 
  • IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. 
  • Identification of Determinants and Implementation Strategies to Increase PrEP Uptake Among Black Same Gender-Loving Men in Mecklenburg County, North Carolina: The PrEP-MECK Study. 
  • Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties. 
  • Illness Perceptions, Medication Beliefs, and Adherence to Antiretrovirals and Medications for Comorbidities in Adults With HIV Infection and Hypertension or Chronic Kidney Disease. 
  • ImPlementation REsearCh to DEvelop Interventions for People Living with HIV (the PRECluDE consortium): Combatting chronic disease comorbidities in HIV populations through implementation research. 
  • Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061. 
  • Immune reconstitution in patients with HIV infection. 
  • Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. 
  • Immuno-virologic outcomes and immuno-virologic discordance among adults alive and on anti-retroviral therapy at 12 months in Nigeria. 
  • Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages. 
  • Impact of Medicare Part D on mental health treatment and outcomes for dual eligible beneficiaries with HIV. 
  • Impact of immediate initiation of antiretroviral therapy on HIV patient satisfaction. 
  • Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy. 
  • Improvements in the HIV care continuum needed to meaningfully reduce HIV incidence among men who have sex with men in Baltimore, US: a modelling study for HPTN 078. 
  • Improving efficiency of inferences in randomized clinical trials using auxiliary covariates. 
  • Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. 
  • Improving participant understanding of informed consent in an HIV-prevention clinical trial: a comparison of methods. 
  • In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir. 
  • Incorporation of Privileged Structures into Bevirimat Can Improve Activity against Wild-Type and Bevirimat-Resistant HIV-1. 
  • Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy. 
  • Influence of HIV antiretrovirals on methadone N-demethylation and transport. 
  • Influence of time stress and other variables on counseling by pharmacists about antiretroviral medications. 
  • Influencing medication adherence among women with AIDS. 
  • Inhibitory effect of PRO 2000, a candidate microbicide, on dendritic cell-mediated human immunodeficiency virus transfer. 
  • Initial multicenter experience with double nucleoside therapy for human immunodeficiency virus infection during pregnancy. 
  • Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor beta chain repertoire and reduces the level of T-cell oligoclonality. 
  • Initiation of antiretroviral therapy in HIV-infected adults with skin complaints in northern Tanzania. 
  • Interactions between highly active antiretroviral therapy and over-the-counter agents: a cautionary note. 
  • Interfacial cavity filling to optimize CD4-mimetic miniprotein interactions with HIV-1 surface glycoprotein. 
  • Interruption of antiretroviral therapy is associated with increased plasma cystatin C. 
  • Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. 
  • Intracellular Tenofovir and Emtricitabine Concentrations in Younger and Older Women with HIV Receiving Tenofovir Disoproxil Fumarate/Emtricitabine. 
  • Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases. 
  • Invasive bacterial and fungal infections among hospitalized HIV-infected and HIV-uninfected adults and adolescents in northern Tanzania. 
  • Investigating Mediators of the Poor Pneumonia Outcomes of Human Immunodeficiency Virus-Exposed but Uninfected Children. 
  • Isolation, Structural Elucidation, and Anti-HIV Activity of Daphnane Diterpenoids from Daphne odora. 
  • Isolation, structure determination, and anti-HIV evaluation of tigliane-type diterpenes and biflavonoid from Stellera chamaejasme. 
  • Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. 
  • Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. 
  • Kidney injury biomarkers during exposure to tenofovir-based preexposure prophylaxis. 
  • Kleinhospitine E and Cycloartane Triterpenoids from Kleinhovia hospita. 
  • LC-MS Identification, Isolation, and Structural Elucidation of Anti-HIV Tigliane Diterpenoids from Wikstroemia lamatsoensis. 
  • Label-Free Measurements of Tenofovir Diffusion Coefficients in a Microbicide Gel Using Raman Spectroscopy. 
  • Label-free analysis of tenofovir delivery to vaginal tissue using co-registered confocal Raman spectroscopy and optical coherence tomography. 
  • Latency reversal and viral clearance to cure HIV-1. 
  • Linking Women Experiencing Incarceration to Community-Based HIV Pre-Exposure Prophylaxis Care: A Qualitative Study. 
  • Linking women experiencing incarceration to community-based HIV pre-exposure prophylaxis care: protocol of a pilot trial. 
  • Living with HIV infection: perceptions of patients with access to care at a non-governmental organization in Chennai, India. 
  • Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine. 
  • Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine. 
  • Longitudinal patterns of initiation, persistence, and cycling on preexposure prophylaxis among female sex workers and adolescent girls and young women in South Africa. 
  • Longitudinal patterns of unmet need for contraception among women living with HIV on antiretroviral therapy in South Africa. 
  • Longitudinal pre-exposure prophylaxis (PrEP) acceptability, initiation and adherence among criminal justice-involved adults in the USA: the Southern PrEP Cohort Study (SPECS) protocol. 
  • Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings. 
  • Low Levels of Physical Activity Among Older Persons Living with HIV/AIDS Are Associated with Poor Physical Function. 
  • Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women. 
  • Low rates of child testing for HIV persist in a high-risk area of East Africa. 
  • Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. 
  • Lower Levels of Antiretroviral Therapy Enrollment Among Men with HIV Compared with Women - 12 Countries, 2002-2013. 
  • Management of HIV in pregnancy. 
  • Management of antiretroviral therapy. 
  • Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. 
  • Managing depression in countries with low and middle incomes: an imperative for human immunodeficiency virus/acquired immune deficiency syndrome care and treatment and general public health. 
  • Marked sex differences in all-cause mortality on antiretroviral therapy in low- and middle-income countries: a systematic review and meta-analysis. 
  • Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk. 
  • Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. 
  • Mechanism of action and resistant profile of anti-HIV-1 coumarin derivatives. 
  • Medical Providers and Harm Reduction Views on Pre-Exposure Prophylaxis for HIV Prevention Among People Who Inject Drugs. 
  • Medication adherence practices of HIV/AIDS case managers: a statewide survey in North Carolina. 
  • Mental Health and Substance Use Among Patients in a North Carolina HIV Clinic. 
  • Metabolic Syndrome Among Antiretroviral Therapy-Naive Versus Experienced HIV-Infected Patients Without Preexisting Cardiometabolic Disorders in Western Kenya. 
  • Military tuberculosis with paradoxical expansion of intracranial tuberculomas complicating human immunodeficiency virus infection in a patient receiving highly active antiretroviral therapy. 
  • Mind the Gap: Gaps in Antidepressant Treatment, Treatment Adjustments, and Outcomes among Patients in Routine HIV Care in a Multisite U.S. Clinical Cohort. 
  • Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview. 
  • Minimizing the Risk of Perinatal Human Immunodeficiency Virus Transmission. 
  • Missed opportunities for religious organizations to support people living with HIV/AIDS: findings from Tanzania. 
  • Mitochondrial toxicity in hearts of CD-1 mice following perinatal exposure to AZT, 3TC, or AZT/3TC in combination. 
  • Modelling the impact of HIV prevention and treatment for men who have sex with men on HIV epidemic trajectories in low- and middle-income countries. 
  • Molecular targets of anti-HIV-1 triterpenes. 
  • Mortality under plausible interventions on antiretroviral treatment and depression in HIV-infected women: an application of the parametric g-formula. 
  • Motivations for Reducing Other HIV Risk-Reduction Practices if Taking Pre-Exposure Prophylaxis: Findings from a Qualitative Study Among Women in Kenya and South Africa. 
  • Mucosal human defensins 5 and 6 antagonize the anti-HIV activity of candidate polyanion microbicides. 
  • Multicentre analysis of second-line antiretroviral treatment in HIV-infected children: adolescents at high risk of failure. 
  • Multicompartmental Pharmacokinetic Model of Tenofovir Delivery to the Rectal Mucosa by an Enema 
  • Multicompartmental pharmacokinetic model of tenofovir delivery by a vaginal gel. 
  • Multiple Overimputation to Address Missing Data and Measurement Error: Application to HIV Treatment During Pregnancy and Pregnancy Outcomes. 
  • Multivalent benzoboroxole functionalized polymers as gp120 glycan targeted microbicide entry inhibitors. 
  • Neurobehavioral assessment of mice after developmental AZT exposure. 
  • Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study Team. 
  • New betulinic acid derivatives for bevirimat-resistant human immunodeficiency virus type-1. 
  • New phorbol ester derivatives as potent anti-HIV agents. 
  • Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. 
  • Newer treatments for HIV in children. 
  • Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials. 
  • Novel Approaches to Postnatal Prophylaxis to Eliminate Vertical Transmission of HIV. 
  • Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus. 
  • Novel function of prothymosin alpha as a potent inhibitor of human immunodeficiency virus type 1 gene expression in primary macrophages. 
  • Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. 
  • On assessing bioequivalence and interchangeability between generics based on indirect comparisons. 
  • One-pot synthesis of an AZT boranophosphate conjugated with tyrosine: a potential prodrug candidate. 
  • Optimization of 2,4-diarylanilines as non-nucleoside HIV-1 reverse transcriptase inhibitors. 
  • Organizational network strengthening effects on antiretroviral therapy initiation and adherence. 
  • Oropharyngeal candidiasis in patients with HIV: suggested guidelines for therapy. 
  • PMTCT Option B+ Does Not Increase Preterm Birth Risk and May Prevent Extreme Prematurity: A Retrospective Cohort Study in Malawi. 
  • Parallel evolution of drug resistance in HIV: failure of nonsynonymous/synonymous substitution rate ratio to detect selection. 
  • Participants' Explanations for Nonadherence in the FEM-PrEP Clinical Trial. 
  • Patient-Initiated Repackaging of Antiretroviral Therapy, Viral Suppression and Drug Resistance. 
  • Patterns and implications of medical pluralism among HIV/AIDS patients in rural South Africa. 
  • Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. 
  • Pediatric AIDS prognosis using somatic growth velocity. 
  • Pediatric HIV infection: the state of antiretroviral therapy. 
  • Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1. 
  • Perceived HIV Acquisition Risk and Low Uptake of PrEP Among a Cohort of Transgender Women With PrEP Indication in the Eastern and Southern United States. 
  • Perceptions of the role of maternal nutrition in HIV-positive breast-feeding women in Malawi. 
  • Perceptions on HIV Pre-Exposure Prophylaxis Among Urgent Care Clinicians in the Southern United States. 
  • Performance of a high-throughput next-generation sequencing method for analysis of HIV drug resistance and viral load. 
  • Performance of creatinine and cystatin C GFR estimating equations in an HIV-positive population on antiretrovirals. 
  • Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation. 
  • Perspectives of Black women in the United States on salon-based intervention to promote the uptake of pre-exposure prophylaxis (PrEP) for HIV. 
  • Persulfated molecular umbrellas as anti-HIV and anti-HSV agents. 
  • Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. 
  • Pharmacokinetics and tolerance of zidovudine in preterm infants. 
  • Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus--infected pregnant women and their neonates: an AIDS clinical trials group study. 
  • Pharmacological considerations in human immunodeficiency virus-infected adults in the intensive care unit. 
  • Phase I/II trial of intermittent subcutaneous IL-2 administration in pediatric patients with moderate immune suppression: results of Pediatric AIDS Clinical Trials Study 402. 
  • Phenotype, Genotype, and Drug Resistance in Subtype C HIV-1 Infection. 
  • Picomolar dichotomous activity of gnidimacrin against HIV-1. 
  • Plasma and Intracellular Concentrations in HIV-Infected Patients Requiring Hemodialysis Dosed With Tenofovir Disoproxil Fumarate and Emtricitabine. 
  • Plasma carnitine in HIV-associated neuropathy. 
  • Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials. 
  • Potent Anti-HIV Ingenane Diterpenoids from Euphorbia ebracteolata. 
  • Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1. 
  • Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. 
  • Potential impact of antiretroviral therapy and screening on cervical cancer mortality in HIV-positive women in sub-Saharan Africa: a simulation. 
  • Potential impact of implementing and scaling up harm reduction and antiretroviral therapy on HIV prevalence and mortality and overdose deaths among people who inject drugs in two Russian cities: a modelling study. 
  • Pre-Exposure Prophylaxis for HIV Infection as a Public Health Tool. 
  • Pre-exposure prophylaxis for people who inject drugs and their sex partners. 
  • Pre-exposure prophylaxis works--it's time to deliver. 
  • Predicting virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania: a cross-sectional study. 
  • Predictors of Self-repackaging of Antiretroviral Therapy in Northern Tanzania. 
  • Predictors of glycaemic control among HIV-positive veterans with diabetes. 
  • Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. 
  • Predictors of mortality in treatment experienced HIV-infected patients in northern Tanzania. 
  • Predictors of non-adherence to antiretroviral therapy among HIV infected patients in northern Tanzania. 
  • Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration. 
  • Prescribing rates and characteristics of recipients of tenofovir-containing regimens before and after market entry of tenofovir alafenamide. 
  • Prevalence and correlates of probable depression diagnosis and suicidal ideation among patients receiving HIV care in Lilongwe, Malawi. 
  • Prevalence and predictors of major depression in HIV-infected patients on antiretroviral therapy in Bamenda, a semi-urban center in Cameroon. 
  • Prevention of cardiovascular disease among people living with HIV in sub-Saharan Africa. 
  • Prevention of cardiovascular disease for historically marginalized racial and ethnic groups living with HIV: A narrative review of the literature. 
  • Prevention-effective adherence trajectories among transgender women indicated for PrEP in the United States: a prospective cohort study. 
  • Preventive Misconception and Risk Behaviors in a Multinational HIV Prevention Trial. 
  • Primary care of HIV infection. 
  • Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy. 
  • Profile of Chronic Comorbid Conditions and Obstetrical Complications Among Pregnant Women With Human Immunodeficiency Virus and Receiving Antiretroviral Therapy in the United States. 
  • Progress in the prevention of mother to child transmission of HIV in three regions of Tanzania: a retrospective analysis. 
  • Prophylaxis after sexual exposure to HIV. 
  • Prothymosin-alpha inhibits HIV-1 via Toll-like receptor 4-mediated type I interferon induction. 
  • Providing Safe and Effective Preventative Antiretroviral Prophylaxis to HIV-exposed Newborns via a Novel Drug Delivery System in Tanzania. 
  • Psychosocial challenges facing women living with HIV during the perinatal period in rural Uganda. 
  • Quantitative analysis of microbicide concentrations in fluids, gels and tissues using confocal Raman spectroscopy. 
  • Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers. 
  • Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). 
  • Rationing HIV medications: what do patients and the public think about allocation policies? 
  • Real-world safety of pre-exposure prophylaxis for HIV. 
  • Receipt and predictors of smoking cessation pharmacotherapy among veterans with and without HIV. 
  • Recovery of interleukin-17 production from interleukin-15-stimulated CD4+ mononuclear cells in HIV-1-infected patients with sustained viral suppression. 
  • Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials. 
  • Relationship between CD4 count, viral burden, and quality of life over time in HIV-1-infected patients. 
  • Resolution of intractable molluscum contagiosum in a human immunodeficiency virus-infected patient after institution of antiretroviral therapy with ritonavir. 
  • Retinal arterioles narrow with increasing duration of anti-retroviral therapy in HIV infection: a novel estimator of vascular risk in HIV? 
  • Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis. 
  • Revisiting Successful Aging With HIV Through a Revised Biopsychosocial Model: An Update of the Literature. 
  • Risk Factors for Incident Hypertension Within 1 Year of Initiating Antiretroviral Therapy Among People with HIV. 
  • Risk factors influencing antibody responses to Kaposi's sarcoma-associated herpesvirus latent and lytic antigens in patients under antiretroviral therapy. 
  • Risk of chronic kidney disease in people living with HIV by tenofovir disoproxil fumarate (TDF) use and baseline D:A:D chronic kidney disease risk score. 
  • Role of human immunodeficiency virus (HIV) type 1 envelope in the anti-HIV activity of the betulinic acid derivative IC9564. 
  • Routine HIV screening in France: clinical impact and cost-effectiveness. 
  • Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial. 
  • Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. 
  • Second-Line HIV Therapy Outcomes and Determinants of Mortality at the Largest HIV Referral Center in Southern Vietnam. 
  • Self-reported zidovudine adherence among pregnant women with human immunodeficiency virus infection in four US states. 
  • Semi-solid gels function as physical barriers to human immunodeficiency virus transport in vitro. 
  • Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. 
  • Sensitivity Analysis of a Pharmacokinetic Model of Vaginal Anti-HIV Microbicide Drug Delivery. 
  • Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. 
  • Seroconversion on preexposure prophylaxis: a case report with segmental hair analysis for timed adherence determination. 
  • Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. 
  • Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels. 
  • Shooting at a moving target: natural history studies and the rapidly improving state of anti-HIV treatment. 
  • Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users. 
  • Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons. 
  • Short-cycle therapy in adolescents after continuous therapy with established viral suppression: the impact on viral load suppression. 
  • Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. 
  • Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up. 
  • Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. 
  • Social, structural, behavioral and clinical factors influencing retention in Pre-Exposure Prophylaxis (PrEP) care in Mississippi. 
  • Status of selected nutrients and progression of human immunodeficiency virus type 1 infection. 
  • Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis. 
  • Stelleralides A-C, novel potent anti-HIV daphnane-type diterpenoids from Stellera chamaejasme L. 
  • Stressful and traumatic life events as disruptors to antiretroviral therapy adherence. 
  • Structure-based identification and neutralization mechanism of tyrosine sulfate mimetics that inhibit HIV-1 entry. 
  • Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques. 
  • Success hinges on support for treatment. 
  • Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries. 
  • Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates. 
  • Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection. 
  • Synthesis and Structure-Activity Relationship Correlations of Gnidimacrin Derivatives as Potent HIV-1 Inhibitors and HIV Latency Reversing Agents. 
  • Synthesis and anti-HIV activity of 2'-deoxy-2'-fluoro-4'-C-ethynyl nucleoside analogs. 
  • Synthesis and anti-HIV activity of bi-functional betulinic acid derivatives. 
  • Synthesis of betulinic acid derivatives as entry inhibitors against HIV-1 and bevirimat-resistant HIV-1 variants. 
  • Synthesis of new 2'-deoxy-2'-fluoro-4'-azido nucleoside analogues as potent anti-HIV agents. 
  • Synthesis, Hydrolysis, and Protonation-Promoted Intramolecular Reductive Breakdown of Potential NRTIs: Stavudine α-P-Borano-γ-P-N-l-tryptophanyltriphosphates. 
  • Tailoring a mobile health text-messaging intervention to promote antiretroviral therapy adherence among African Americans: A qualitative study. 
  • Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus. 
  • Taste and smell complaints in HIV-infected patients. 
  • Technologies for global health. 
  • Tenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy. 
  • Tenofovir alafenamide for HIV infection: is less more? 
  • Terpenes from Euphorbia antiquorum and Their in Vitro Anti-HIV Activity. 
  • Test site predicts HIV care linkage and antiretroviral therapy initiation: a prospective 3.5 year cohort study of HIV-positive testers in northern Tanzania. 
  • The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha. 
  • The HIV Care Continuum among Female Sex Workers: A Key Population in Lilongwe, Malawi. 
  • The HIV-positive traveler. 
  • The Impact of Preexposure Prophylaxis Among Men Who Have Sex With Men: An Individual-Based Model. 
  • The Influence of Social Networks on Antiretroviral Therapy Initiation Among HIV-Infected Antiretroviral Therapy-Naive Youth in Rural Kenya and Uganda. 
  • The Path to Implementation of HIV Pre-exposure Prophylaxis for People Involved in Criminal Justice Systems. 
  • The Relationship Between Efavirenz as Initial Antiretroviral Therapy and Suicidal Thoughts Among HIV-Infected Adults in Routine Care. 
  • The association between substance use and sub-optimal HIV treatment engagement among HIV-infected female sex workers in Lilongwe, Malawi. 
  • The changing epidemiology of HIV-related chronic kidney disease in the era of antiretroviral therapy. 
  • The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. 
  • The connection between serious life events, anti-retroviral adherence, and mental health among HIV-positive individuals in the Western Cape, South Africa. 
  • The differential binding and activity of PRO 2000 against diverse HIV-1 envelopes. 
  • The discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIV. 
  • The effects of HHV-8 vMIP-II on SIVmac251 infection and replication competent and incompetent SIVmac239Delta3 vectors. 
  • The global response and unmet actions for HIV and sex workers. 
  • The global response to HIV in men who have sex with men. 
  • The impact of mental health and traumatic life experiences on antiretroviral treatment outcomes for people living with HIV/AIDS. 
  • The influence of psychosocial characteristics and race/ethnicity on the use, duration, and success of antiretroviral therapy. 
  • The name game: lamivudine-lamotrigine dispensing error presenting as human immunodeficiency virus-associated fever of unknown origin. 
  • The potential effect of COVID-19-related disruptions on HIV incidence and HIV-related mortality among men who have sex with men in the USA: a modelling study. 
  • The potential uses of preexposure prophylaxis for HIV prevention among people who inject drugs. 
  • The regional pattern of abnormal cerebrovascular reactivity in HIV-infected, virally suppressed women. 
  • The role of HIV-DNA testing in clinical practice. 
  • The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid. 
  • The spectrum of kidney disease in patients with AIDS in the era of antiretroviral therapy. 
  • The syndemic effects of mental ill health, household hunger, and intimate partner violence on adherence to antiretroviral therapy among pregnant women living with HIV in Yaoundé, Cameroon. 
  • The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328. 
  • Thymic function, aging, and AIDS. 
  • Tigliane-Type Diterpene Esters from the Fruits of Shirakiopsis indica and Their Anti-HIV Activity. 
  • Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors. 
  • To dose-adjust or not to dose-adjust: lamivudine dose in kidney impairment. 
  • Topical microbicides: the time has come. 
  • Total lymphocyte count and World Health Organization pediatric clinical stage as markers to assess need to initiate antiretroviral therapy among human immunodeficiency virus-infected children in Moshi, Northern Tanzania. 
  • Trajectories of Depressive Symptoms, Neurocognitive Function, and Viral Suppression With Antiretroviral Therapy Among Youth With HIV Over 36 months. 
  • Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men. 
  • Transmethylamine-N-Oxide Is Associated With Diffuse Cardiac Fibrosis in People Living With HIV. 
  • Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007. 
  • Trauma history and depression predict incomplete adherence to antiretroviral therapies in a low income country. 
  • Treating depression within the HIV "medical home": a guided algorithm for antidepressant management by HIV clinicians. 
  • Treatment and CD4+ T cell count recovery among antiretroviral therapy-naive patients with HIV/AIDS. 
  • Treatment retention and care transitions during and after the scale-up of HIV care and treatment in Northern Tanzania. 
  • Trends in human immunodeficiency virus (HIV) counseling, testing, and antiretroviral treatment of HIV-infected women and perinatal transmission in North Carolina. 
  • Trends in interventions to reduce perinatal human immunodeficiency virus type 1 transmission in North Carolina. 
  • Tryptophan degradation is associated with risk-taking propensity in methamphetamine users with treated HIV infection. 
  • Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. 
  • Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. 
  • US trade action threatens Brazilian AIDS programme. 
  • Understanding of Perceived Infectiousness and Its Influence on Sexual Behavior Among Individuals With Acute HIV Infection in Lilongwe, Malawi (HPTN 062). 
  • Understanding the HIV Epidemic Among MSM in Baltimore: A Modeling Study Estimating the Impact of Past HIV Interventions and Who Acquired and Contributed to Infections. 
  • Urine processing impacts uric acid level in HIV-infected adults: implications for diagnosing tenofovir-associated proximal tubulopathy. 
  • Urolithiasis under atazanavir boosted and tenofovir therapy: a case report. 
  • Use of a human-centered design approach to adapt a nurse-led cardiovascular disease prevention intervention in HIV clinics. 
  • Use of glomerular filtration rate estimating equations for drug dosing in HIV-positive patients. 
  • Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation. 
  • Utilization of health care services in hard-to-reach marginalized HIV-infected individuals. 
  • Utilization of medical treatments and adherence to antiretroviral therapy among HIV-positive adults with histories of childhood sexual abuse. 
  • Vaginal deployment and tenofovir delivery by microbicide gels. 
  • Vaginal drug distribution modeling. 
  • Vaginal film for prevention of HIV: using visual and tactile evaluations among potential users to inform product design. 
  • Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. 
  • Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism. 
  • Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope. 
  • Virologic response of nine therapy-experienced children receiving 64 weeks of nelfinavir salvage therapy. 
  • When and why women might suspend PrEP use according to perceived seasons of risk: implications for PrEP-specific risk-reduction counselling. 
  • When children harbor HIV. 
  • Whose priorities? A response to the issue of antiretrovirals in Africa. 
  • You can always pop a pill. 
  • Zidovudine administered to women infected with human immunodeficiency virus type 1 and to their neonates reduces pediatric infection independent of an effect on levels of maternal virus. 
  • Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. 
• 

  Keywords of People

  • Ferrari, Guido, Professor in Surgery, Molecular Genetics and Microbiology
  • Katz, David F., Nello L. Teer, Jr. Distinguished Professor of Biomedical Engineering, in the Edmund T. Pratt, Jr. School of Engineering, Biomedical Engineering